Expert Interviews

ACIP recommendations for the most appropriate older population for the RSV vaccine has shifted and the NFID medical director explains why.

Rebecca Hartman, MD, MHP, assistant professor of dermatology at Brigham and Women's Hospital and Harvard Medical School, reviews new point-of-care detection technology.

Topical corticosteroids, once revolutionary for treatment of atopic dermatitis, are used just sparingly today; dermatologist Mona Shahriari, MD, lists the reasons.

Dermatologist Rebecca Hartman, MD, MPH, said that reliable point-of-care screening results can help reduce unnecessary specialist referral for benign lesions.

Not all atopic dermatitis requires treatment by a specialist, says this dermatologist, and she collaborates regularly with her primary care colleagues.

The DermaSensor skin cancer screening device was pitted against clinical impressions of lesions suspected with high confidence to be melanoma. Results, here.

Dermatologists at high volume dermatology centers referred suspicious lesions to pathology for biopsy and diagnosis. The results were compared with DermaSensor read-outs.

A rapid increase in the rate of melanoma diagnoses could be the result of multiple factors, explains the Harvard assistant professor of dermatology.

A bothersome skin lesion is typically first seen and assessed in primary care. An AI-based point-of-care device may help enhance triage, says Rebecca Hartman, MD, MPH.

Shahriari, assistant clinical professor of dermatology at Yale University School of Medicine, says greater understanding of the condition has expanded the population for the diagnosis.

Dermatology thought leader Mona Shihriari, MD, offers a brief overview of the inflammatory skin disease for primary care clinicians.

Women who receive a false positive breast cancer screening result may forego future mammograms. Thoughtfully counsel any young patient who may be feeling this way.

After a false positive breast cancer screening result, women may be reluctant to participate in future screening, a topic that could benefit from the primary care touch.

Caissa Troutman, MD, provides an overview of the connection between obesity and hypertension.

Even after adjusting for breast density, studies reveal a significantly greater risk for a cancer diagnosis within 2 decades. A UC Davis expert offers details.

A false positive finding on a screening mammogram is fairly common, according to UC Davis biostatistician Diana Miglioretti, PhD. Here's why.

The group of women least likely to return for a regular preventive screening mammogram after a false positive result surprised this primary investigator.

After a false positive outcome on screening mammography, a short interval call back for repeat imaging was a significant deterrent to future screening.

The most common harm associated with breast cancer screening is a false positive finding; this UC Davis expert wanted to know more about how women respond.

Building trust with patients early on will help them feel comfortable discussing their symptoms and treatment preferences, says JoAnn Pinkerton, MD.

Less than 15% of women in menopause receive treatment for VMS, suggesting a need a for more education and awareness, according to JoAnn Pinkerton, MD.

An expert discussion with JoAnn Pinkerton, MD, national lead for the OASIS clinical trial program of elinzanetant for moderate-to-severe VMS.

JoAnn Pinkerton, MD, national lead for the OASIS clinical trial program evaluating elinzanetant for menopausal VMS, discusses how non-hormonal therapy differs from HRT.

Surya Bhatt, MD, MSPH, is coprincipal investigator for the 2 pivotal phase 3 clinical trials that supported today's landmark FDA approval of dupilumab for COPD.

JoAnn Pinkerton, MD, details the positive findings from the OASIS 1, 2, and 3 studies of elinzanetant and highlights next steps in research.

Experts on diabetes provide insights gleaned from the SIMPLE study and outline patient factors that inform treatment decisions.

Medha Munshi, MD, leads a comprehensive discussion on diabetes treatment practices and discusses the role of deprescribing and other treatment adjustments in older adult patients.

Continuing the discussion on a 68-year-old patient, the panel discusses the importance of follow-up and the benefits of combination therapies in older adults.

Focusing on diabetes testing and treatment practices, Conan Tu, MD, MBA, DACD, BC-ADM, presents the profile of a 68-year-old new patient who presents with symptoms in line with a family history of type 2 diabetes.

Conan Tu, MD, MBA, DACD, BC-ADM, presents a case of an 84-year-old patient with diabetes experiencing medication burden and glycemic control challenges.